Analgesia-Based Sedation During Mechanical Ventilation

NCT ID: NCT00403208

Last Updated: 2006-11-28

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

280 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-03-31

Study Completion Date

2006-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Hypothesis: A protocolized algorithm for sedation in critically ill patients on mechanical ventilation can decrease ventilator days, costs and improve outcome.

This is a multicenter observational-interventional study on critically ill patients who require mechanical ventilation for more than 48 hours, involving 13 ICU in Chile. There are two periods (groups): a descriptive phase of sedation practices, and an interventional period in which an analgesia-based, goal-directed, nurse-driven sedation is applied.

Main outcome: ventilator-free days between both periods.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a multicenter observational-interventional study on critically ill patients who require mechanical ventilation for more than 48 hours, involving 13 ICU in Chile.

Main exclusion criteria are neurologic impairment, previous chronic cardiac, liver and renal failure, second period of mechanical ventilation during hospitalization, short term expected mortality.

There is an initial descriptive phase of sedation practice, involving sedative drugs, sedation level assessment, and outcome: ventilator-free days, ICU stay, costs and mortality.

After a period of analysis and training, an analgesia-based, goal-directed, nurse-driven sedation protocol is applied. Fentanyl infusion is started and titrated to obtain a patient calm and cooperative or mildly sedated while on mechanical ventilation. Hypnotics and opiates i.v. boluses are allowed during the first hours of mechanical ventilation. Midazolam infusion is started if ventilatory distress continue despite fentanyl 1.8 µg/kg/min. Haldol, muscle relaxants and other sedative drugs are allowed depending on patient condition. After 48 hours of mechanical ventilation, sedative drugs are discontinued in the morning.

Main outcome: ventilator-free days. Secondary outcome: ICU stay, costs, and sedation quality. At 6 moths SF-36. Each period is planned to included at least 140 patients, for a 20% difference in ventilator-free days, with 80% power and a 0.05 type I error.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Ventilation, Mechanical Respiratory Insufficiency Critical Illness

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Ventilation, Mechanical Sedation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Analgesia based sedation in ICU patients

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients who require mechanical ventilation for more than 48 hours

Exclusion Criteria

* Nervous system diseases
* Previous liver or renal failure
* Second episode of MV during same hospitalization
* Expected MV shorter than 48 hours
* Short term expected mortality.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Pontificia Universidad Catolica de Chile

OTHER

Sponsor Role lead

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Guillermo Bugedo, MD

Role: PRINCIPAL_INVESTIGATOR

Universidad Catolica de Chile

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hospital Regional de Coquimbo

Coquimbo, , Chile

Site Status RECRUITING

Hospital Universidad Catolica de Chile

Santiago, , Chile

Site Status RECRUITING

Clinica Alemana

Santiago, , Chile

Site Status RECRUITING

Hospital Clinico Universidad de Chile

Santiago, , Chile

Site Status RECRUITING

Hospital Dipreca

Santiago, , Chile

Site Status RECRUITING

Hospital Luis Tisne

Santiago, , Chile

Site Status RECRUITING

Hospital Militar

Santiago, , Chile

Site Status RECRUITING

Hospital Padre Hurtado

Santiago, , Chile

Site Status ACTIVE_NOT_RECRUITING

Hospital San Jose

Santiago, , Chile

Site Status ACTIVE_NOT_RECRUITING

Hospital San Juan de Dios

Santiago, , Chile

Site Status RECRUITING

Hospital Sotero del Rio

Santiago, , Chile

Site Status RECRUITING

Hospital Regional de Talca

Talca, , Chile

Site Status RECRUITING

Hospital Carlos Van Buren

Valparaíso, , Chile

Site Status RECRUITING

Hospital Naval

Viña del Mar, , Chile

Site Status NOT_YET_RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Chile

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Guillermo Bugedo, MD

Role: CONTACT

Phone: 562 3543972

Email: [email protected]

Eduardo Tobar

Role: CONTACT

Phone: 562 3543972

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Hector Ugarte

Role: primary

Guillermo Bugedo

Role: primary

Eduardo Tobar

Role: backup

Vinko Tomicic

Role: primary

Jose Castro

Role: primary

Jose Castro

Role: primary

Pilar Lora

Role: primary

Antonio Hernandez

Role: primary

Hugo Gonzalez

Role: primary

Jorge Godoy

Role: primary

Juan Jara

Role: primary

Eduardo Encalada

Role: primary

Eduardo Labarca

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

SA05I20091

Identifier Type: -

Identifier Source: org_study_id